The world is in a fierce competition with the COVID-19 virus constantly mutating (E484K, N501Y) and increasing its resistance to the recently approved vaccines. Amidst all these, one bio-tech company chose to find a treatment to the virus that will overcome its mutating ability rather than developing a vaccine.
Located in Israel, TrioxNano Ltd is known for its technology particularly by developing programmable biologic nano carriers that can accurately deliver payloads to their target.
Now, they are in the process of donning another feather in their cap through their novel TNB (Triox Nano Biotics) technology that can be programmed to treat different viral infections including the Covid19 and its mutated versions.
We, at InsightsCare, had the opportunity to learn more about the company and its pathbreaking discoveries.
Below are the highlights of the interview:
Please brief our audience about your company, its values, vision, and mission.
TrioxNano’s revolutionary technology, termed S.M.A.R.T, an acronym for Stimuli Multi Adjusted Responsive Technology, or simply put “Programmable medicine” is based on combinations of DNA coding, DNA molecular machines and mesoporous nanoparticles. S.M.A.R.T offers the potential to program most approved medications, increasing their efficacy exponentially. TrioxNano is granted world approved patents for its programming abilities.
To create S.M.A.R.T we had to first invent the modular hardware that will allow incorporation of different medications, the software language which is based on DNA coding and the actual codes that will control the modular particle. Our technology is expected to create a paradigm shift and highly impact human lives around the globe, transforming medicine from its current primitive analog state to a programmable digital modern era.
TrioxNano is driven by a team of highly intelligent, motivated, forward thinking scientists. All have hands on experience of years in the industry. We chose chemists and biologists that are integrators, able to bridge the gap between these two worlds. As an Israeli company we try to think out the box and “cut to the chase” as much as possible basing our decisions on sound science.
What are the prominent services and products, that your company offers?
We offer our programmable technology called S.M.A.R.T to the pharma industry. Any single medication molecule currently approved has the potential to be profoundly more effective and less toxic once programming is added to it. It is estimated that more than 1000 approved medication can be delivered by this programmable system and at least 500 unique programs can be uploaded to them.
This adds up to about half a million different options of unique treatments (in the case that only one code is uploaded per particle), in the case a combination of three codes is loaded and estimated 125 billion treatment options are created.
Being an experienced leader, what is your opinion on the adaptation of newer technological developments to sustain business competency?
I believe human’s strongest trait is adaptation and flexibility. As humanity develops, we become more open minded and less suspicious of forward thinking new technologies. The use of DNA/RNA for treatments of human disease received substantial backwind with the development of Pfizer and Moderna’s Covid19 Vaccine. Our DNA nanotechnology is taking this a step further using DNA as building blocks to created programmable machines that are utilized for the treatment of cancer and covid19.
Taking into consideration, the current pandemic, and its impact on global economies, how are you driving your organization to sustain operations?
We have also adapted ourselves to the Covid19 pandemic, by developing our own treatment alternatives utilizing the vast knowledge created in our organization for DNA nanotechnology. We are now developing both our programmed cancer treatment and TNB to treat COVID-19.
Where do you envision your organization to be in the long run and what are your future goals?
To achieve our goal of programmed medicine and as pioneers in the field we are developing in parallel three fields: hardware (the modular platform able to carry the molecules), software (the methods codes are interacting with the platform) and code writing (the commands to actually control it). We aspire to be the next Intel (developing the hardware required to run the operation system and the code). And Microsoft (creating the operating system for computerized drug delivery).
We are currently coding the technology ourselves based on known literature variable in a parallel to developing a process that will automatically check billions of options at a time but envision a day that other groups to code the relevant commands to control the technology. We want to revolutionize the way patients are treated! We offer the path toward a paradigm shift that will highly impact human lives, transforming medicine from an analog state to an exciting programmable digital modern era.
About the leader
Roy Farfara, MD founded TrioxNano with a vision of transforming medicine as we know it, from an analog nonspecific era to a digital programmable era using programmable DNA nanotechnology. As a surgeon being aware of the limitation of surgery (hoping to resect micrometer size cancer cells with one thousand times larger tools) nonspecific chemotherapies having small efficacy and substantial toxicity in cancer patients. Immunotherapy is an exciting and effective approach, but it too is currently being done in an analog way and could benefit greatly from our programming abilities.